Reports Q3 adjusted EBITDA C$18.479M vs. C$15.372M in the previous quarter. “Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market. We achieved record quarterly net revenue of C$76.2M in our global medical cannabis business through double-digit growth internationally, led by Germany and Poland. Adjusted EBITDA rose sequentially to C$18.5M and we generated free cash flow of C$15.5M. These results validate our focused strategy and reinforce our confidence in the company’s future,” said Miguel Martin, Executive Chairman and CEO for Aurora.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Options Volatility and Implied Earnings Moves Today, February 04, 2026
- Options Volatility and Implied Earnings Moves This Week, February 02 – February 06, 2026
- Aurora Cannabis (US) (ACB) Q3 Earnings Cheat Sheet
- Aurora Cannabis initiated with a Buy at Canaccord
- Aurora Cannabis Sets February 4 Call to Discuss Q3 2026 Results